Asian Spectator

.
Business Advice

.

Octa’s compelling Ramadan 2023—Memories which become templates for the future

KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 27 March 2024 - It is time to recall all the Ramadan initiatives the international broker Octa has launched and curated throughout the last year. C...

yeedi Redefines Robot Mops with the Debut of yeedi mop station

Europe’s first self-cleaning robot mop & vacuum that washes the mopping pads automaticallyBERLIN, GERMANY - Media OutReach - 7 July 2021 -yeedi, a robot vacuum brand committed to...

Aismixer Launches Its Coin Shuffle Service Platform, Protecting Users' Privacy

Hong Kong, May 23, 2021 - (ACN Newswire) - Recently, Aismixer has announced the launching of its coin shuffle platform which can protect users' privacy to the maximum extent. Coin shuffle, i...

People Across The Globe Come Together To Celebrate New York's ...

NEW YORK, Dec. 29, 2020 /PRNewswire-AsiaNet/ -- -- Leaders from as far as Germany, India, Japan, Mexico, South Africa, and Spain, and Mayors from cities as close as Atlanta, Boston, Houston...

Stay Fit, Stay Active 24/7 in Quarantine @ Dorsett Wanchai

From HK$800nett/night with daily 3 meals & up to US$281 Cash Credits upon booking including the newly introduced ‘Fitness Suite’ featuring in-suite treadmill & yoga set &...

DEBIOPHARM AND ASPEN PARTNER TO LAUNCH PROSTATE CANCER DRUG TR...

LAUSANNE, Switzerland and DURBAN, South Africa, Feb. 1, 2022, /PRNewswire-AsiaNet/ -- Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company and Aspen, a South African headquarte...

Gunung Raja Paksi bolsters commitment to the production of sustainable steel in Southeast Asia via two MoU signings with Fortescue Future Industries and KADIN

The recent new MoU signings are in line with GRP’s mission to decarbonise the regional steel industry as outlined in its most recently launched ESG Strategy Handbook JAKARTA, INDONESIA...

Huawei Releases the Striding Towards the Intelligent World - D...

BANGKOK, Sept. 23, 2022 /PRNewswire-AsiaNet/ -- At HUAWEI CONNECT 2022, David Wang, Huawei's Executive Director of the Board and Chairman of ICT Infrastructure Managing Board, released a ser...

CellCarta acquires Biogazelle to strengthen its genomic capabi...

MONTREAL, Dec. 14, 2021 /PRNewswire-AsiaNet/ -- -- This acquisition solidifies CellCarta's leadership position in genomic services with a unique combination of assay development and global c...

Eisai to Present New Research on Eribulin (Halaven) at 42nd Annual San Antonio Breast Cancer Symposium

Eisai to Present New Research on Eribulin (Halaven) at 42nd Annual San Antonio Breast Cancer Symposium

TOKYO, Dec 5, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that the latest information on its in-house discovered and developed eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: HALAVEN, "eribulin") will be presented during the 42nd San Antonio Breast Cancer Symposium (SABCS2019). The symposium will be held from December 10 through 14, 2019, in San Antonio, Texas in the United States.

Eisai to Present New Research on Eribulin (Halaven) at 42nd Annual San Antonio Breast Cancer Symposium

A total of five poster presentations will be given at this year's SABCS including the study results evaluating absolute lymphocyte count at the baseline with eribulin as a predictor of overall survival from the post-hoc analysis of two Phase III clinical studies of eribulin in patients with advanced or metastatic breast cancer.Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer. Eisai will continue to create innovation in the development of new drugs based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.

About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

In its medium-term business plan EWAY2025, Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions), and is working on establishment of ecosystem platform business utilizing various data such as a large amount of clinical data, experiences, and know-how.

For more information about Eisai Co., Ltd., please visit https://www.eisai.co.jp.

Contact:Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Copyright 2019 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

Disparitas pemidanaan: mengapa pelaku kekerasan seksual bisa mendapat hukuman berbeda-beda untuk kasus serupa?

Ilustrasi korban kekerasan seksual.Tinnakorn jorruang/ShutterstockPraktik hukum di Indonesia masih menunjukkan adanya disparitas pemidanaan, yakni ketika ada dua orang atau lebih melakukan tindak pida...

8 aspek penting untuk memastikan keberlanjutan industri nikel dari hulu ke hilir

Isu mengenai hilirisasi nikel Indonesia tengah panas beberapa tahun ke belakang. Ambisi Presiden Joko Widodo untuk menjadikan Indonesia sentra produksi baterai kendaraan listrik (EV) dunia membuat akt...

Gangguan dismorfik tubuh: apa yang perlu kita ketahui tentang kondisi kesehatan mental ini

Selebritas Megan Fox dalam sebuah wawancara dengan Sports Illustrated mengungkapkan bahwa dia memiliki dismorfik tubuh (body dysmorphia). Fox mengatakan: “Saya tidak pernah melihat diri saya sep...



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion